- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07399678
과체중/비만 참가자(제2형 당뇨병 유무 관계없이)에서 ALV-100의 안전성, 내약성 및 약동학/약력학을 평가하는 연구
과체중 또는 비만 환자(제2형 당뇨병 유무에 관계없이)를 대상으로 ALV-100의 안전성, 내약성, 약동학 및 약력학을 평가하는 1b상 무작위 배정, 이중 맹검, 위약 대조, 용량 증량 연구
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Florida
-
Miami, Florida, 미국, 33172
- Clinical Pharmacology of Miami
-
-
Ohio
-
Columbus, Ohio, 미국, 43212
- Ohio Clinical Trials
-
-
Texas
-
San Antonio, Texas, 미국, 78240
- Endeavor Clinical Trials
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
For Part A and B
- Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
- Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
- Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
- Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
- Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.
For Part B only
- Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
- Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
- Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.
Exclusion Criteria:
For Part A and B
- History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
- Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
- Current or history of chronic or acute pancreatitis.
- Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
- History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
- Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
- Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
- History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.
Part A only
• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).
Part B only
- Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
- Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
- Severe neuropathy as judged by the investigator.
- Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
- History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part A - Cohort 1 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
위약 비교기: Part A - Cohort 1 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
실험적: Part A - Cohort 2 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
위약 비교기: Part A - Cohort 2 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
실험적: Part A - Cohort 3 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
위약 비교기: Part A - Cohort 3 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
실험적: Part A - Cohort 4 (ALV-100)
Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
위약 비교기: Part A - Cohort 4 (Placebo)
Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
|
실험적: Part B - T2D Cohort (ALV-100)
Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection. |
Participants will receive multiple ascending doses of ALV-100. |
|
위약 비교기: Part B - T2D Cohort (Placebo)
Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection. |
Participants will receive placebo matching ALV-100, volume-matched to active dose. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety and tolerability
기간: From First Dose to Week 52
|
Incidence of treatment emergent adverse events (TEAEs) |
From First Dose to Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - Cmax, MD
기간: From First Dose to Week 52
|
Maximum observed serum concentration after multiple doses (MD) (Cmax, MD) |
From First Dose to Week 52
|
|
Pharmacokinetics (PK) of intact ALV-100 and total ALV-100 - AUC(0-τ), MD
기간: From First Dose to Week 52
|
Area under the serum concentration-time curve from time zero to τ, where τ is the dosing interval, (AUC(0-τ), MD) |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact on body weight
기간: Baseline, Week 32 and Week 52
|
Change from baseline in body weight |
Baseline, Week 32 and Week 52
|
|
Pharmacodynamic (PD) impact on body weight percentage
기간: Baseline, Week 32 and Week 52
|
Change from baseline in body weight percentage |
Baseline, Week 32 and Week 52
|
|
Immunogenicity
기간: From Baseline to Week 52
|
Incidence of Anti-ALV-100 drug antibodies, including assessments of cross-reactivity and neutralizing antibodies. |
From Baseline to Week 52
|
|
Relationship between ALV-100 serum concentration and QTc interval changes (Part A Only)
기간: From First Dose to Week 52
|
Measurement of change in individual specific heart rate corrected QT interval (QTcI) and Fridericia heart rate corrected QT interval (QTcF) on 12-lead ECG. |
From First Dose to Week 52
|
|
Paracetamol (acetaminophen) absorption test (PAT) (Part A Only)
기간: From First Dose to Week 52
|
Measurement of acetaminophen PK parameters to evaluate the effect of ALV-100 on the gastric emptying rate. |
From First Dose to Week 52
|
|
Pharmacodynamic (PD) impact of ALV-100 on antidiabetic medication (Part B Only)
기간: From Baseline to Week 32
|
Change in use of concomitant glucose-lowering medication |
From Baseline to Week 32
|
|
Pharmacodynamic (PD) impact of ALV-100 on glycemic parameters (Part B Only)
기간: Week 32 and Week 52
|
Measuring the number of participants achieving target Hemoglobin A1c values |
Week 32 and Week 52
|
|
Hypoglycemic Safety (Part B Only)
기간: From Baseline to Week 52
|
Measured by the incidence of symptomatic hypoglycemia, documented symptomatic hypoglycemia and severe hypoglycemia |
From Baseline to Week 52
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Karen Tornøe, MD, PhD, Alveus Therapeutics
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ALV-102-1
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .